Navigation Links
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Date:11/3/2008

Top-line data from randomized, double-blind, placebo controlled Phase 2 clinical trial indicate statistically significant reduction in recurrences

of CDAD

PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective. The top-line results from the recently completed multi- center, randomized, double-blind, placebo-controlled Phase 2 trial indicated a statistically significant reduction in recurrences of CDAD when compared with placebo. In the study, 200 patients symptomatic with CDAD receiving standard of care antibiotics (metronidazole or vancomycin) were randomized to receive either intravenous placebo or intravenous administration of a combination of MDX-066 (CDA-1) and MDX-1388 (CDB-1), two fully human antibodies that neutralize C. difficile toxins A and B, respectively.

Consistent with the published literature, the recurrence rate in the placebo-treated group exceeded 20 percent for patients following successful treatment with standard of care antibiotics. In comparison with placebo, MDX- 066/MDX-1388 treatment reduced recurrence rates by approximately 70 percent (p=0.0004 on the intent-to-treat population). The antibody combination treatment was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.

The incidence and mortality associated with CDAD has been increasing(1),
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Medarex Announces 2008 Third Quarter Financial Results
2. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
3. Medarex to Present at the UBS Global Life Sciences Conference
4. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
5. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
6. Medarex Announces July 10 Live Webcast of R&D Day Event
7. Medarex to Present at the Jefferies Second Annual Healthcare Conference
8. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
9. Medarex to Present at the Bank of America 2008 Healthcare Conference
10. Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... CA (PRWEB) August 19, 2014 Robin ... Parkinson’s disease can take on an individual. Symptoms ... decreased facial expression, problems swallowing and severe depression. ... the dying off of dopamine producing neurons of the ... from a disease that slowly and progressively gets worse, ...
(Date:8/19/2014)... , Aug. 19, 2014 ... addition of the "Spectroscopy Equipment and ... report to their offering. ... Spectroscopy Equipment and Accessories in US$ Thousands ... (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... Inc. (NASDAQ: AUXL ), a specialty biopharmaceutical ... of post-approval use in the U.S. of XIAFLEX® for ... palpable cord.  After approximately 11,000 injections administered to approximately ... meaningful change in the nature of events expected relative ...
... 2011 Genprex, Inc., formerly known as Convergen ... nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™ ... brand in the oncology sector in recognition of our ... will be used to unlock the unrealized potential of ...
... - QIAGEN assay for JAK2 V617F mutation ... ,JAK2 inhibitor, and to monitor responses to therapy ... exclusive access to JAK2 biomarker underpins potential future expansion with ... QGEN ; Frankfurt, Prime Standard: QIA) today announced that ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 3QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 4
(Date:8/19/2014)... at San Antonio and The University of Texas at ... than $750,000 in grants through the San Antonio Life ... SALSI is a model of how a general academic ... forces for greater research and graduate education. , The ... public health issues and diseases of global impact. Funding ...
(Date:8/19/2014)... August 2014: An engineer at the University of Liverpool ... a brain to communicate with the body. , Dr ... Mahadevan, has developed a mathematical model for earthworms and ... these soft bodied animals get around. , The most ... generator (CPG) which states that the central brain of ...
(Date:8/19/2014)... study that analyzed concentrations of African dust transported ... winter and spring. These research findings offer new ... quality impacts of African dust, including the climate ... occur from increased African dust emissions in the ... (UM) Rosenstiel School of Marine and Atmospheric Science ...
Breaking Biology News(10 mins):San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3Secrets of how worms wriggle uncovered 2Study of African dust transport to South America reveals air quality impacts 2
... , The University of Haifa, Israel, has dedicated Israel,s ... focus on research and development of non-irrigated green roofs; ... and evolutionary theories. The center has been ... expert in the field, and was facilitated by VP ...
... Investigators at Washington University and The Scripps Research Institute ... to facilitate meta-analyses on studies of the metabolism of ... of the Global Metabolomic Initiative was sent to more ... a total of more than 35,000 files of metabolomic ...
... und MÜNCHEN, 7. November 2012 Bausch + Lomb, ... er seine Option zum Kauf aller im Umlauf befindlichen ... GmbH (TPV) ausgeübt hat, einem führenden Hersteller ophthalmologischer Lasersysteme. ... aus einem Joint Venture zwischen Bausch + Lomb und ...
Cached Biology News:Israel's first Green Roofs Ecology research center dedicated at University of Haifa 2Global metabolomic initiative announced 2Global metabolomic initiative announced 3Global metabolomic initiative announced 4Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 2Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 3Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 4
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
... structure has been determined, the challenge is ... diverse audience of scientists, educators and students. ... dissemination over the Internet, either via online ... Printed literature has the advantage of wide ...
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
Biology Products: